Prescription medications that treat obesity work in different ways, according to the National Institutes of Health
After the initial interaction, the activated CD8+ T cells trigger downstream cytokine/chemokine production and epidermal keratinocyte apoptosis through the Fas/Fas ligand (FasL) pathway and TCR/HLA pathway
However, the incidence of clinically meaningful muscle wasting under GLP-1RA therapy remains to be determined through prospective studies with standardized assessment methods
This raises the possibility that Ipamorelin may not only promote gastric muscle contractility but also possibly offset the inhibitory effects resulting from certain surgical procedures
Study author Sun H Kim, MD, MS, Associate Professor of Medicine in the Division of Endocrinology, Gerontology, and Metabolism at Stanford, summarized the findings to to Medical News Today , saying: We found that semaglutide compared to other weight loss medications, including another GLP-1 medication called dulaglutide, reduced risk of future fractures despite being associated with greater weight loss. Overall, semaglutide was linked to a bigger decrease in BMI
